Vistin Pharma Asa · OSL:VISTN
Vistin Pharma Asa — Q1 2020 Earnings Presentation
19 slides from Vistin Pharma Asa's earnings presentation, Apr 23, 2020
Slide 1: Vistin Pharma - First quarter 2020
Vistin Pharma - First quarter 2020 Kjell-Erik Nordby (CEO) Alexander Karlsen (CFO) 23 April 2020 1
Slide 2: Agenda
Agenda Highlights Operational review - pharmaceuticals MEP – Metformin expansion project Financial review Summary & outlook Appendix 2
Slide 3: Highlights First quarter 2020
HIGHLIGHTS First quarter 2020 Pharmaceuticals: 45% increase in revenue and a record quarterly result - Revenue of NOK 61.4 million for the quarter vs. NOK 42.2 million in Q1 2019 - Sales volumes 43% higher than Q1 2019, however less volume was available for sale in Q1-19, due to an extended stop i
Slide 4: Agenda
Agenda Highlights Operational review - pharmaceuticals MEP – Metformin expansion project Financial review Summary & outlook Appendix 4
Slide 5: Vistin Pharma a dedicated metformin producer with a bright outlook
OPERATIONAL REVIEW - PHARMACEUTICALS Vistin Pharma a dedicated metformin producer with a bright outlook DIABETES METFORMIN A BRIGHT OUTLOOK - - FOR VISTIN PHARMA ONE OF THE THE GOLD STANDARD - LARGEST HEALTH + TREATMENT OF TYPE = A LEADING GLOBAL EMERGENCIES IN THE 2 DIABETES PRODUCER OF 21ST CENTUR
Slide 6: Diabetes – A global emergency
OPERATIONAL REVIEW - PHARMACEUTICALS Diabetes – A global emergency Diabetes in perspective: 1 of 7 births is affected by gestational diabetes 1 in 11 adults has diabetes Every 6 seconds a person dies from diabetes Number of people living with diabetes Source International Diabetes Federation
Slide 7: 43% increase in sales volume vs Q1-19
OPERATIONAL REVIEW - PHARMACEUTICALS 43% increase in sales volume vs Q1-19 Sales volume for the first quarter was 873MT Sales volume metformin (HCl & DC) (608MT Q1 2019) Metric tonnes per quarter The production plant has been running at full capacity Sales volume for Q2 is confirmed at full ca
Slide 8: Business update and Corona virus epidemic consequences
OPERATION UPDATE Business update and Corona virus epidemic consequences The Fikkjebakke plant is running at full capacity - Actions are taken to secure the supply of critical raw materials and to build security stocks There are no reported corona infected employees in Vistin Pharma as of today -
Slide 9: Agenda
Agenda Highlights Operational review - pharmaceuticals MEP – Metformin expansion project Financial review Summary & outlook Appendix 9
Slide 10: Expansion of the manufacturing capacity to 7000MT approved by the Board
OPERATIONAL REVIEW Expansion of the manufacturing capacity to 7000MT approved by the Board Summary Growing demand from existing customers will exceed Vistin’s manufacturing capacity going forward Strong and stable underlying growth in the metformin market Strong demand for Vistin Pharma’s prem
Slide 11: Agenda
Agenda Highlights Operational review - pharmaceuticals MEP – Metformin expansion project Financial review Summary & outlook Appendix 11
Slide 12: Key quarterly figures for Vistin Pharma
FINANCIAL REVIEW Key quarterly figures for Vistin Pharma (figures for continuing operations) Revenue (pharmaceuticals) NOK million 68 61 61 NOK 19 million (+45%) higher revenue YoY – 55 57 higher sales volume and favourable EUR/NOK 53 53 exchange rate 41 42 - Q1 19 was affected by an extended main
Slide 13: Consolidated income statement
FINANCIAL REVIEW Consolidated income statement (NOK 1 000) Q1 2020 Q1 2019 FY 2019 Total revenue and income Pharmac eutic als 61 407 42 234 228 130 Energy Trading - - - HQ & other - - - Total revenue and inc ome 61 407 42 234 228 130 EBITDA Pharmac eutic als 14 238 (1 542) 30 358 Energy Trading 74 (
Slide 14: Financial position
FINANCIAL REVIEW Financial position (NOK 1 000) 31.03.2020 31.03.2019 31.12.2019 Property, plant & equipment 101 288 98 379 101 802 Inventory 24 498 27 090 24 107 Trade receivables 40 011 22 032 38 277 Cash & cash equivalents 316 792 299 550 319 672 Other 47 668 35 496 20 306 Total Assets 530 257 48
Slide 15: Agenda
Agenda Highlights Operational review - pharmaceuticals MEP – Metformin expansion project Financial review Summary & outlook Appendix 15
Slide 16: Summary & outlook
Summary & outlook Metformin market expected to continue to grow by 4-5% annually - Diabetes is one of the largest health crises of the 21st century - Metformin is expected to maintain its position as the Gold Standard treatment for T2D in the foreseeable future Attractive growth potential from e
Slide 17: Agenda
Agenda Highlights Operational review - pharmaceuticals MEP – Metformin expansion project Financial review Summary & outlook Appendix 17
Slide 18: Top shareholders as of March 2020
APPENDIX Top 20 shareholders as of 31 March 2020 18
Slide 19: Thank you for your attention!
Thank you for your attention! www.vistin.com 19